- Home
- MARPS vs SNGX Comparison
MARPS vs SNGX Comparison
Compare MARPS & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- SNGX
- Stock Information
- Founded
- MARPS 1956
- SNGX 1987
- Country
- MARPS United States
- SNGX United States
- Employees
- MARPS N/A
- SNGX N/A
- Industry
- MARPS Oil & Gas Production
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MARPS Energy
- SNGX Health Care
- Exchange
- MARPS Nasdaq
- SNGX Nasdaq
- Market Cap
- MARPS 7.6M
- SNGX 7.4M
- IPO Year
- MARPS N/A
- SNGX 1987
- Fundamental
- Price
- MARPS $4.37
- SNGX $2.35
- Analyst Decision
- MARPS
- SNGX
- Analyst Count
- MARPS 0
- SNGX 0
- Target Price
- MARPS N/A
- SNGX N/A
- AVG Volume (30 Days)
- MARPS 11.6K
- SNGX 619.7K
- Earning Date
- MARPS 01-01-0001
- SNGX 03-14-2025
- Dividend Yield
- MARPS 8.15%
- SNGX N/A
- EPS Growth
- MARPS N/A
- SNGX N/A
- EPS
- MARPS 0.36
- SNGX N/A
- Revenue
- MARPS $1,042,513.00
- SNGX $364,183.00
- Revenue This Year
- MARPS N/A
- SNGX N/A
- Revenue Next Year
- MARPS N/A
- SNGX $76.64
- P/E Ratio
- MARPS $12.16
- SNGX N/A
- Revenue Growth
- MARPS N/A
- SNGX N/A
- 52 Week Low
- MARPS $3.76
- SNGX $1.83
- 52 Week High
- MARPS $6.50
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- MARPS 65.21
- SNGX 34.04
- Support Level
- MARPS $4.20
- SNGX $2.03
- Resistance Level
- MARPS $4.67
- SNGX $3.44
- Average True Range (ATR)
- MARPS 0.19
- SNGX 0.33
- MACD
- MARPS 0.04
- SNGX -0.08
- Stochastic Oscillator
- MARPS 65.12
- SNGX 19.39
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).